A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma

Trial Profile

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs AZD 1208 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Apr 2016 Pooled analysis of 2 studies, including 35 patients from this trial and 32 patients from another study [see CTP 700211022] were presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 18 Aug 2015 Trial focus is changed from AR TO TU as reported by ClinicalTrials.gov record
    • 12 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top